JP2015509535A5 - - Google Patents

Download PDF

Info

Publication number
JP2015509535A5
JP2015509535A5 JP2014561024A JP2014561024A JP2015509535A5 JP 2015509535 A5 JP2015509535 A5 JP 2015509535A5 JP 2014561024 A JP2014561024 A JP 2014561024A JP 2014561024 A JP2014561024 A JP 2014561024A JP 2015509535 A5 JP2015509535 A5 JP 2015509535A5
Authority
JP
Japan
Prior art keywords
halo
cyano
optionally substituted
pharmaceutical composition
hydrocarbyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014561024A
Other languages
English (en)
Japanese (ja)
Other versions
JP6418950B2 (ja
JP2015509535A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/029056 external-priority patent/WO2013134228A1/en
Publication of JP2015509535A publication Critical patent/JP2015509535A/ja
Publication of JP2015509535A5 publication Critical patent/JP2015509535A5/ja
Application granted granted Critical
Publication of JP6418950B2 publication Critical patent/JP6418950B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014561024A 2012-03-09 2013-03-05 ピラゾロ[1,5−a]ピリミジン系化合物、それを含む組成物、及びそれらを使用する方法 Active JP6418950B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261608765P 2012-03-09 2012-03-09
US61/608,765 2012-03-09
PCT/US2013/029056 WO2013134228A1 (en) 2012-03-09 2013-03-05 PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE

Publications (3)

Publication Number Publication Date
JP2015509535A JP2015509535A (ja) 2015-03-30
JP2015509535A5 true JP2015509535A5 (enExample) 2016-04-21
JP6418950B2 JP6418950B2 (ja) 2018-11-07

Family

ID=47892052

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014561024A Active JP6418950B2 (ja) 2012-03-09 2013-03-05 ピラゾロ[1,5−a]ピリミジン系化合物、それを含む組成物、及びそれらを使用する方法

Country Status (25)

Country Link
US (3) US8946415B2 (enExample)
EP (1) EP2834243B1 (enExample)
JP (1) JP6418950B2 (enExample)
KR (1) KR101965025B1 (enExample)
CN (1) CN104302649B (enExample)
AR (1) AR090292A1 (enExample)
AU (1) AU2013230128B2 (enExample)
BR (1) BR112014022000A8 (enExample)
CA (1) CA2866143C (enExample)
DK (1) DK2834243T3 (enExample)
ES (1) ES2676224T3 (enExample)
HU (1) HUE038786T2 (enExample)
IL (1) IL234486A (enExample)
IN (1) IN2014DN07384A (enExample)
MX (2) MX381849B (enExample)
NZ (1) NZ630721A (enExample)
PL (1) PL2834243T3 (enExample)
PT (1) PT2834243T (enExample)
RU (1) RU2014140735A (enExample)
SG (1) SG11201405561RA (enExample)
TR (1) TR201808280T4 (enExample)
TW (1) TW201341386A (enExample)
UY (1) UY34668A (enExample)
WO (1) WO2013134228A1 (enExample)
ZA (1) ZA201406149B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014022000A8 (pt) 2012-03-09 2021-06-15 Lexicon Pharmaceuticals Inc compostos à base de pirazol[1,5-a]pirimidina, seu uso e composições que os compreende
EP2822559B1 (en) 2012-03-09 2018-05-02 Lexicon Pharmaceuticals, Inc. Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and uses thereof
US8901305B2 (en) 2012-07-31 2014-12-02 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
JP2016509066A (ja) 2013-02-22 2016-03-24 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company アダプター関連キナーゼ1(aak1)の阻害剤としての5h−クロメノ[3,4−c]ピリジン
TW201542550A (zh) * 2013-09-06 2015-11-16 Lexicon Pharmaceuticals Inc 吡唑并[1,5-a]嘧啶基化合物、包含彼之組合物以及使用彼之方法
ES2678877T3 (es) 2013-10-11 2018-08-20 Bristol-Myers Squibb Company Inhibidores de pirrolotriazina quinasa
RS59059B1 (sr) 2014-01-24 2019-08-30 Turning Point Therapeutics Inc Diaril makrociklična jedinjenja kao modulatori protein kinaza
CN106132951B (zh) * 2014-01-31 2019-02-12 百时美施贵宝公司 基于喹啉的激酶抑制剂
TW201620911A (zh) * 2014-03-17 2016-06-16 雷西肯製藥股份有限公司 銜接子關聯激酶1之抑制劑、包含其之組成物、及其使用方法
EP3200797A1 (en) * 2014-09-30 2017-08-09 Bristol-Myers Squibb Company Quinazoline-based kinase inhibitors
HUE067779T2 (hu) * 2014-12-15 2024-11-28 Cmg Pharmaceutical Co Ltd Kondenzált gyûrûs heteroaril vegyületek és azok felhasználása TRK inhibitorokként
EP3292124B1 (en) 2015-04-10 2019-05-22 Bristol-Myers Squibb Company 6h-isochromeno[3,4-c]pyridines and benzo[c][1,7]naphthyridin-6-(5h)-ones as adaptor associated kinase 1 (aak1) inhibitors
CN107735399B (zh) 2015-07-02 2021-01-26 特普医药公司 作为蛋白质激酶的调节剂的手性二芳基大环
PL3319969T3 (pl) 2015-07-06 2024-06-24 Turning Point Therapeutics, Inc. Diarylowe polimorfy makrocykliczne
RU2020123800A (ru) 2015-07-21 2020-10-02 Тёрнинг Поинт Терапьютикс, Инк. Хиральные диарильные макроциклы и их применение
CN108349979B (zh) 2015-11-02 2021-04-09 詹森药业有限公司 [1,2,4]三唑并[1,5-a]嘧啶-7-基化合物
AU2017302019A1 (en) 2016-07-28 2019-02-07 Turning Point Therapeutics, Inc. Macrocycle kinase inhibitors
TWI764950B (zh) * 2016-11-02 2022-05-21 比利時商健生藥品公司 Pde2抑制劑
EA039847B1 (ru) 2016-11-02 2022-03-18 Янссен Фармацевтика Нв СОЕДИНЕНИЯ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2
BR112019008163A2 (pt) 2016-11-02 2019-07-09 Janssen Pharmaceutica Nv compostos de [1,2,4]triazolo[1,5-a]pirimidina como inibidores de pde2
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
DK3658557T3 (da) 2017-07-28 2024-07-29 Takeda Pharmaceuticals Co Tyk2-inhibitorer og anvendelser deraf
KR102645316B1 (ko) 2017-07-28 2024-03-07 터닝 포인트 테라퓨틱스, 인크. 거대환형 화합물 및 이의 용도
MX2020006293A (es) * 2017-12-15 2020-12-03 Pyramid Biosciences Inc Derivados de 5-(2-2,5-difluorofenil)pirrolidin-1-il)-3-(1h-pirazol -1-il)pirazolo[1,5-a]pirimidina y compuestos relacionados como inhibidores de trk cinasa para el tratamiento de cancer.
JP7194188B2 (ja) 2017-12-19 2022-12-21 ターニング・ポイント・セラピューティクス・インコーポレイテッド 疾患を治療するための大環状化合物
JP7150356B2 (ja) * 2017-12-22 2022-10-11 深▲チェン▼市塔吉瑞生物医薬有限公司 置換ピラゾロ[1,5-a]ピリミジン化合物並びにその医薬組成物および使用
EP3744723B1 (en) 2018-01-23 2023-10-18 Shenzhen TargetRx, Inc. Substituted pyrazolo[1,5-a]pyrimidine macrocyclic compound
US20220041588A1 (en) * 2018-09-27 2022-02-10 Fochon Pharmaceuticals, Ltd. Substituted imidazo[1,2-a]pyridine and [1,2,4]triazolo[1,5-a]pyridine compounds as ret kinase inhibitors
JP7619951B2 (ja) * 2018-10-15 2025-01-22 武田薬品工業株式会社 Tyk2阻害剤およびその使用
CA3175973A1 (en) * 2020-04-21 2021-10-28 Lexicon Pharmaceuticals, Inc. 4-(3-(pyridin-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl)piperazine for use in the the treatment of cov-229e or cov-oc43 coronaviruses infections
CA3175970A1 (en) 2020-04-21 2021-10-28 Suma GOPINATHAN Aak1 inhibitors for use in treating viral infections
US11478733B2 (en) 2020-11-24 2022-10-25 Caterpillar Inc. Filter interlock with tabs mating with a pedestal or a housing
WO2025054448A1 (en) * 2023-09-08 2025-03-13 Satellos Bioscience Inc. Ap2 associated kinase 1 inhibitors and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US6194410B1 (en) * 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
JP4847275B2 (ja) * 2005-10-21 2011-12-28 田辺三菱製薬株式会社 ピラゾロ[1,5−a]ピリミジン化合物
KR20090073121A (ko) 2006-09-29 2009-07-02 노파르티스 아게 Pi3k 지질 키나제 억제제로서의 피라졸로피리미딘
US20120058997A1 (en) * 2006-11-06 2012-03-08 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
AU2009246687B2 (en) * 2008-05-13 2012-08-09 Irm Llc Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
BRPI0919873B8 (pt) * 2008-10-22 2021-05-25 Array Biopharma Inc compostos de pirazol[1,5-a]pirimidina substituídos como inibidores da trk quinase, seus processos de preparação e composições farmacêuticas
AR077468A1 (es) * 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
US8865726B2 (en) 2009-09-03 2014-10-21 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors
EP2523552B1 (en) * 2010-01-14 2015-05-13 Merck Sharp & Dohme Corp. Pyrazolo[1,5-a]pyrimidines as mark inhibitors
ES2671748T3 (es) * 2011-07-21 2018-06-08 Tolero Pharmaceuticals, Inc. Inhibidores heterocíclicos de proteína quinasas
BR112014022000A8 (pt) 2012-03-09 2021-06-15 Lexicon Pharmaceuticals Inc compostos à base de pirazol[1,5-a]pirimidina, seu uso e composições que os compreende
AU2013230066A1 (en) * 2012-03-09 2014-09-25 Lexicon Pharmaceuticals, Inc. Inhibition of adaptor associated kinase 1 for the treatment of pain
EP2822559B1 (en) 2012-03-09 2018-05-02 Lexicon Pharmaceuticals, Inc. Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and uses thereof
TW201620911A (zh) * 2014-03-17 2016-06-16 雷西肯製藥股份有限公司 銜接子關聯激酶1之抑制劑、包含其之組成物、及其使用方法

Similar Documents

Publication Publication Date Title
JP2015509535A5 (enExample)
JP2015509534A5 (enExample)
JP2016529319A5 (enExample)
JP2016529315A5 (enExample)
JP2016540742A5 (enExample)
JP2013537203A5 (enExample)
JP2015537020A5 (enExample)
JP2017504635A5 (enExample)
JP2017514830A5 (enExample)
JP2016514159A5 (enExample)
JP2013542261A5 (enExample)
JP2018524390A5 (enExample)
JP2017519781A5 (enExample)
CY1118107T1 (el) Παραγωγα ετεροαρυλιου ως διαμορφωτες αλφα7 nachr
JP2014506907A5 (enExample)
JP2015531773A5 (enExample)
JP2014511892A5 (enExample)
JP2014500861A5 (enExample)
JP2014037426A5 (enExample)
JP2011529054A5 (enExample)
JP2016505614A5 (enExample)
JP2017505293A5 (enExample)
JP2017511321A5 (enExample)
JP2017514910A5 (enExample)
JP2019510794A5 (enExample)